Pharmaceuticals

GUANGJI PHARMA

GUANGJI PHARMA released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 163.09 M, actual EPS CNY -0.0913

GUANGJI PHARMA released FY2025 Annual Earnings on April 24 After-Market (BJT), with actual revenue of CNY 623.97 M and EPS of CNY -1.1613

GUANGJI PHARMA released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 194.71 M, actual EPS CNY -0.8861

GUANGJI PHARMA to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

GUANGJI PHARMA FY2025 Annual Earnings Release on April 25, 2026 After-Market (BJT)

GUANGJI PHARMA released FY2025 Q3 earnings on October 26 After-Market (BJT), actual revenue CNY 144.91 M, actual EPS CNY -0.0628

GUANGJI PHARMA released FY2025 9 Months Earnings on October 26 After-Market (BJT), actual revenue CNY 429.26 M, actual EPS CNY -0.2786

GUANGJI PHARMA FY2025 Q3 Earnings Release on October 27, 2025 After-Market (BJT)

GUANGJI PHARMA released FY2025 Q2 earnings on August 28 Pre-Market BJT, actual revenue CNY 135.87 M, actual EPS CNY -0.112

GUANGJI PHARMA released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue CNY 284.36 M, actual EPS CNY -0.2158

GUANGJI PHARMA to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Guangji Pharmaceutical Expected Net Loss of 67-83.5 Million Yuan in H1 2025

Guangji Pharmaceutical 2'-FL Product Passes National Approval

Guangji Pharmaceutical's ESG Rating Downgraded from A to BB

Huizhou Pharmaceutical Fined 1.5M for Disclosure Violations

Jikang Pharmaceutical and Guangdong Rongtai Pharmaceutical Strategic Cooperation Signing Ceremony

Guangji Pharmaceutical Released Q1 2025 Earnings Report

Guangji Pharmaceutical Announces Significant Net Profit Decline in 2024 Annual Report

GUANGJI PHARMA released FY2024 Q4 earnings on April 27 After-Market BJT, actual revenue CNY 176.61 M, actual EPS CNY -0.3907

GUANGJI PHARMA released FY2025 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 148.49 M, actual EPS CNY -0.1037

002945

601872

601899

02899

000952

36Kr learned that the three major A-share indices opened lower collectively, with the Shanghai Composite Index down 0.2%, the Shenzhen Component Index down 0.42%, and the ChiNext Index down 0.63%; the brokerage, retail, and precious metals sectors led the decline, with CLS down 5%, Shanghai Jiubai down over 4%, and Zijin Mining down over 1%; the shipping, pharmaceutical, and internet sectors saw the largest gains, with CMES up over 5%, GUANGJI PHARMA up over 4%, and Yanshan Technology up over 2%

36Kr

CMES

Zijin Mining

ZIJIN MINING

The three major A-share indices opened lower collectively, and the precious metals sector weakened

300638

300223

301292

According to the data from the Dragon and Tiger List on December 1st, institutions net bought Ingenic, Guoke Technology, and GUANGJI PHARMA, with amounts of 251 million yuan, 147 million yuan, and 77.21 million yuan, respectively. Institutions net sold Hi-Tech Spring, Jereh, and Fibocom, with amounts of 142 million yuan, 128 million yuan, and 85.12 million yuan, respectively

Fibocom

Ingenic

Hi-Tech Spring

Institutions bought 16 stocks including Ingenic today and sold Hi-Tech Spring for 142 million yuan

000788

605188

601116

The A-shares closed today with the ChiNext Index opening low and rising over 2%, while the consumer sector strengthened towards the end of trading. The Shanghai Composite Index fluctuated within a narrow range throughout the day, closing down 0.15%; the Shenzhen Component Index rose 1.02%; the ChiNext Index increased by 2.14%. Pharmaceutical stocks were strong, with GUANGJI PHARMA and PKU HEALTHCARE hitting the daily limit. CPO and other computing hardware stocks performed well, with Zhongji Xuchuang soaring over 10%. The consumer sector surged towards the end, with GUOGUANG CHAINS and Sanjiang Shopping Club hitting the daily limit. The military industry sector collectively adjusted, with Jiuzhiyang and Jianglong Shipbuilding dropping over 10%. Most individual stocks fell rather than rose, with over 3,500 stocks in the Shanghai, Shenzhen, and Beijing markets showing losses, and the trading volume nearing 1.8 trillion

Wallstreetcn

PKU HEALTHCARE

GUOGUANG CHAINS

Sanjiang Shopping Club

A-shares closing: The ChiNext index opened lower but rose over 2%, with the consumer sector strengthening in the closing minutes

According to the Zhitong Finance APP, GUANGJI PHARMA disclosed its third-quarter report for 2025. The company achieved revenue of 429 million yuan in the first three quarters, a year-on-year decrease of 7.12%; the net profit attributable to the parent company was a loss of 97.3 million yuan; the net profit excluding non-recurring gains and losses was a loss of 101 million yuan; basic earnings per share were -0.2789 yuan

Zhitong

GUANGJI PHARMA released its performance for the first three quarters, with a net loss attributable to the parent company of 97.3 million yuan

On October 26th, GUANGJI PHARMA announced that in the third quarter of 2025, it achieved operating revenue of 145 million yuan, a year-on-year decrease of 12.57%; the net loss attributable to shareholders of the listed company was 21.7836 million yuan; basic earnings per share were -0.0628 yuan

GUANGJI PHARMA: Net loss of 21.7836 million yuan in the third quarter

GUANGJI PHARMA's subsidiary Hubei Huisheng Pharmaceutical Co., Ltd. recently received the re-registration approval notice for Vitamin B6 chemical raw materials issued by the Hubei Provincial Drug Administration. This batch ensures the stability and continuity of the production and sales qualifications for Vitamin B6

GUANGJI PHARMA's subsidiary has received the re-registration approval notice for Vitamin B6 chemical raw materials

According to the Zhitong Finance APP, GUANGJI PHARMA released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 284 million yuan, a year-on-year decrease of 4.08%. The net loss attributable to shareholders of the listed company was 75.5151 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 78.4109 million yuan, with a basic loss per share of 0.2158 yuan

GUANGJI PHARMA released its performance for the first half of the year, with a net loss attributable to the parent company of 75.5151 million yuan

GUANGJI PHARMA announced that the administrative license application for 2'-fucosyllactose submitted by the company has passed the review by the National Health Commission and has been announced. 2'-FL is a oligosaccharide that is abundant in breast milk and has various functions. GUANGJI PHARMA's 2'-FL has officially passed approval and obtained a new variety license for food additives, marking an important progress in the field of synthetic biology applications for the company. However, the future production, market acceptance, sales situation, and performance may still be affected by uncertainties such as changes in market demand and adjustments in policies and regulations

GUANGJI PHARMA: 2'-Fucosyllactose Approved

GUANGJI PHARMA announced that it has received the "Advance Notice of Administrative Penalty" from the Hubei Regulatory Bureau of the China Securities Regulatory Commission. Due to suspected violations of information disclosure, the Hubei Regulatory Bureau intends to impose a fine of 1.5 million yuan on the company, and a fine of 800,000 yuan each on the then Chairman and Chief Financial Officer. The company is not involved in significant illegal circumstances that would lead to mandatory delisting, and the final penalty result will be subject to the "Administrative Penalty Decision" issued by the Hubei Regulatory Bureau

GUANGJI PHARMA: Received a notice of administrative penalty in advance

The Shanghai Municipal Health Commission released the "2025 Shanghai Health and Health Work Key Points," covering 37 items, with a focus on promoting the development of medical artificial intelligence and improving the reproductive support policy system. It plans to implement a fertility subsidy system, focusing on health technology innovation and digital transformation, building a clinical decision knowledge base and industry corpus, formulating data circulation and utilization standards, and promoting Shanghai to become a source of health technology innovation

Huatai-PB CSI Chinese Medicine ETF

Shanghai Municipal Health Commission: Promote the development of medical artificial intelligence and advance the improvement of the fertility support policy system

GUANGJI PHARMA(000952.SZ)